

Fig. 1






Fig. 2




**Fig 3**


PCT/US05/14210

■ Fig 4

4A



4B



4C




Fig.5

# Platelets and plasma of angiogenic and non-angiogenic liposarcoma bearing SCID mice




FIG. 6





Fig. 7










Fig. 9

Fig. 10




Fig 11

## Angiogenic Regulators Within Platelets

⊕ Positive	⊖ Negative
VEGF-A	PF-4
VEGF-C	Thrombospondin
bFGF	NK1, NK2, NK3 fragments of HGF
HGF	
Angiopoietin-1	TGF-beta-1
PDGF	Plasminogen (angiostatin)
EGF	High molecular weight kininogen (domain 5)
IGF-1	Fibronectin (45 kD fragment)
IGF BP-3	EGF (fragment)
Vitronectin	Alpha-2 antiplasmin (fragment)
Fibronectin	Beta-thromboglobulin
Fibrinogen	Endostatin
Heparanase	

*Folkman, Browder, & Palmblad, Thrombosis & Haemostasis 86: 23, 2001.*

<b>Sphingosine-1 PO<sub>4</sub></b>	<b>BDNF (brain derived neurotrophic factor)</b>
-------------------------------------	---

*Y. Yatomi, et al., Blood 86: 193, 1995.*

*Donovan et al., Development 127: 4531, 2000.*

Fig. 12

Matrigel 100 $\mu$ l  
(50 ng  $^{125}$ I VEGF)




Fig. 13




Fig 14

**Non-angiogenic vs angiogenic human liposarcoma  
in nude mice. Luciferase luminescence at 133 days.**




Fig 15

# **Platelet and Plasma Protein Expression Protocol using SELDI-TOF**




Fig 16

**Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).**






Fig 17

**Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).**




Fig 18

**Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).**




Fig 19

# Non-angiogenic human liposarcoma (< 1 mm.)

Time course of sequestration of bFGF in platelets of tumor-bearing mice.

Only molecular weight of 1820 Daltons included.




Figure 20A




Figure 20b

Platelet

Control

Dormant  
tumor

Aggressive  
tumor

Plasma

7500

8000

8500

9000

7500

8000

8500

9000

PF4  
CTAP

PCT/US05/14210

10/5/25/16




Figure 21




Figure 2|





Figure 22

22A Platelet CTAPIII



22B Plasma CTAPIII






Figure 22





Figure 23a



**Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).**




Fig. 23 B

Figure 24





Figure 25



PCT/US05/14210

10/25/2006

7 (1) / 535 7 18

Figure 26